Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P08069
UPID:
IGF1R_HUMAN
Alternative names:
Insulin-like growth factor I receptor
Alternative UPACC:
P08069; B1B5Y2; Q14CV2; Q9UCC0
Background:
The Insulin-like growth factor 1 receptor (IGF1R), a receptor tyrosine kinase, is pivotal in mediating the effects of IGF1. It binds IGF1 with high affinity, playing a crucial role in cell growth, survival, and tumor transformation. IGF1R's activation triggers multiple signaling pathways, including PI3K-AKT/PKB and Ras-MAPK, essential for cellular proliferation and inhibition of apoptosis.
Therapeutic significance:
IGF1R's involvement in Insulin-like growth factor 1 resistance, characterized by growth retardation and altered IGF1 levels, underscores its therapeutic potential. Targeting IGF1R could offer novel strategies for managing this disorder and possibly other malignancies reliant on IGF1R signaling.